Prophylaxis against fungal infections in solid organ and hematopoietic stem cells transplantation Profilaxis antifúngica en niños y adultos sometidos a trasplante de órganos sólidos y de precursores hematopoyéticos
Author
dc.contributor.author
Rabagliati, Ricardo
Author
dc.contributor.author
Elena Santolaya, M.
Admission date
dc.date.accessioned
2019-03-15T16:03:29Z
Available date
dc.date.available
2019-03-15T16:03:29Z
Publication date
dc.date.issued
2012
Cita de ítem
dc.identifier.citation
Revista Chilena de Infectologia, Volumen 29, Issue SUPPL.1, 2018, Pages 11-18
Identifier
dc.identifier.issn
07161018
Identifier
dc.identifier.other
10.4067/S0716-10182012000500002
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/165840
Abstract
dc.description.abstract
Invasive fungal infections are an important cause of morbidity and mortality in SOT and HSCT recipients. The main species involved are Candida spp. and Aspergillus spp, less frequently Cryptococcus spp., causal agents of mucormycosis and Fusarium spp. Usually occur within the first six months post-transplant, but they do it later, especially during episodes of rejection, which maintains the state of immune system involvement. Prophylaxis recommendations are specific to each type of transplant. In liver transplantation use of fluconazole is recommended only in selected cases by high risk factor for invasive fungal infections (A1). If the patient has a high risk of aspergillosis, there are some suggestions for adults population to use amphotericin B-deoxycholate, liposomal amphotericin B or caspofungin (C2) without being validated none of these recommendations in pediatric population. In adult lung transplant patients where the risk of aspergillosis is higher than in other locations, we
Prophylaxis against fungal infections in solid organ and hematopoietic stem cells transplantation Profilaxis antifúngica en niños y adultos sometidos a trasplante de órganos sólidos y de precursores hematopoyéticos